Pages
Products
Support
CBpromise

Our promise to you:
Guaranteed product quality, expert customer support.

24x7 CUSTOMER SERVICE
CONTACT US TO ORDER

OVCAR-5 Cell Line

General Information
Organism Homo sapiens, human
Cell Line Description OVCAR-5 is a human adenocarcinoma cell line established by Thomas C. Hamilton at the Fox Chase Cancer Center from the ascites of a 67-year-old Caucasian female patient; it is distributed as part of the NCI-60 panel of tumor cell lines. The cells grow as an adherent monolayer and exhibit a polygonal, epithelial-like morphology. They are characterized by a homozygous KRAS p.Gly12Val activating mutation. The cell line is microsatellite-stable, capable of growth in soft agar with high colony-forming efficiency, and can induce peritoneal carcinomatosis following intraperitoneal inoculation into immunodeficient mice. OVCAR-5 is widely utilized within the NCI-60 anticancer drug screening platform for research into resistance to platinum-based agents and taxanes, the evaluation of PI3K and mTOR pathway inhibitors, the development of EGFR-targeted photoimmunotherapy models, and genome-wide RNA interference and CRISPR-based profiling. It also serves as a standard reference cell line in high-throughput pharmacological analyses. The cell line is suitable for both monolayer culture and anchorage-independent growth assays, and it is frequently employed in comparative studies across various epithelial ovarian cancer models within the NCI-60 panel.
Tissue Ovary; derived from metastatic site (ascites)
Disease High-grade serous adenocarcinoma (transcriptomic and CA19.9 evidence has also suggested a possible upper gastrointestinal origin)
Morphology Epithelial-like; polygonal
Gender Female
Age 67 years
Ethnicity Caucasian
Product Format Frozen
Growth Mode Adherent
Biosafety Level 1 (Biosafety classification is based on U.S. Public Health Service Guidelines)
Applications 1. Reference ovarian cancer line within the NCI-60 anticancer drug screening panel
2. Cisplatin and paclitaxel resistance mechanisms in epithelial ovarian cancer
3. PI3K/mTOR dual pathway inhibitor evaluation
4. EGFR-targeted photoimmunotherapy and peritoneal carcinomatosis models
5. Genome-scale RNA interference and CRISPR dependency mapping
6. Soft agar anchorage-independent growth and colony formation assays
Shipped In Dry ice
Storage Temperature −196°C
Characteristics
Tumorigenic Yes, produces peritoneal carcinomatosis in immunodeficient mice after intraperitoneal inoculation
Karyotype Modal chromosome number not reported; array-CGH, SNP array and copy number data are available
Genetic Profile KRAS p.Gly12Val (c.35G>T), homozygous
Expression Markers Diffusely positive for CA19.9 by immunocytochemistry
Mycoplasma Test Negative
Viral Status Negative for EBV, HBV, HCV, HIV-1, HIV-2, HTLV-1, HTLV-2 and MLV by PCR
Culture Conditions and Handling
Subculturing 1. Remove and discard the culture medium.
2. Briefly rinse the cell monolayer with PBS (Ca²⁺/Mg²⁺-free) to thoroughly remove residual serum.
3. Add 2.0 to 3.0 mL of 0.25% Trypsin–0.53 mM EDTA solution, and observe under an inverted microscope until the cell monolayer has dispersed (typically takes 2 to 5 minutes).
4. Add 6.0 to 8.0 mL of complete growth medium, and gently pipette to prepare a single-cell suspension.
5. Aliquot the cell suspension into new culture vessels.
Medium Renewal Every 2 to 3 days
Subcultivation Ratio A split ratio of 1:3 to 1:8 is recommended.
Culture Conditions Atmosphere: Air, 95%; CO2, 5%; Temperature: 37°C
Cryopreservation Complete growth medium supplemented with 5% to 10% (v/v) DMSO

The above is only part of a part of cell line products. If you don't find the cell line you want, Creative Biogene can also provide stable cell line generation service with the best prices and fastest turnaround time for you! Contact us for more information or to request a quote.

* For research use only. Not intended for any clinical use.
Quick Inquiry